Direktorat Registrasi ObatValid

IBRANCE

BPOM Number: DKI2158501617C1
Approved: 28 June 2026
Expiry: 15 April 2031
Form: TABLET SALUT SELAPUT

About This Registration

IBRANCE is a BPOM-registered direktorat registrasi obat in Indonesia, registered under number DKI2158501617C1. Its current registration status is Valid, with the licence valid until 15 April 2031. The product is registered to PFIZER INDONESIA - INDONESIA. BPOM first approved this registration in April 2026. All registration data is sourced directly from the official BPOM public database and updated daily.

Registration data updated by BPOM

This product's registration details were changed on 5 July 2026. This may reflect a status change, renewal, or correction by BPOM.

Registration Details

Application: newaero
Packaging: DUS, 1 BLISTER @ 7 TABLET SALUT SELAPUT
Department: Direktorat Registrasi Obat
Data Last Updated: 5 July 2026

Retail Audit Service

Get detailed market intelligence for this product across Indonesian retail channels

Multiple cities available

Custom questionnaires

Professional shoppers

Detailed reporting

Starting from $50 per city

What's included in the audit service?

Stock availability and positioning verification

Price checking and competitor analysis

Display quality and promotional material assessment

Store condition and customer experience evaluation

Custom questions tailored to your research needs

Professional photographs and detailed reports

Registered Owners

PFIZER INDONESIA - INDONESIA
KODYA JAKARTA TIMUR
NPWP: 010000958052000
owner
View profile →

Manufacturing Sites

PFIZER INDONESIA - INDONESIA
KODYA JAKARTA TIMUR
primary
View profile →

Ingredients (1)

PALBOCICLIB

Market Intelligence

Owner Portfolio: PFIZER INDONESIA - INDONESIA holds 164 BPOM registrations
Manufacturer Scale: PFIZER INDONESIA - INDONESIA produces 164 registered products
Registration Age: Registered for 4 months
Update Status: Recently updated (65 days ago)

FDA Cross-Reference

via openFDA

Generic Name: PALBOCICLIB
Product Type: HUMAN PRESCRIPTION DRUG
Route of Administration: ORAL

Data sourced from the U.S. FDA drug label database (openFDA). May not exactly match this product variant.

Is this your product?